A decade of letrozole: FACE

por O’Shaughnessy, Joyce
Publicado 2007

A decade of letrozole: FACE

por O’Shaughnessy, Joyce
Publicado 2008

Treatment options for patients with HR+/HER2− advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy

por O’Shaughnessy, Joyce
Publicado 2020

The hedgehog pathway in triple‐negative breast cancer

por Habib, Joyce G., O'Shaughnessy, Joyce A.
Publicado 2016

nab-Paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis

por O’Shaughnessy, Joyce, Gradishar, William J., Bhar, Paul, Iglesias, Jose
Publicado 2013

Highlights of the 2015 San Antonio Breast Cancer Symposium

por Keaton, Mark, Tripathy, Debu, O'Shaughnessy, Joyce, Tang, Shou-Ching
Publicado 2016

Investigating potential immune mechanisms of trilaciclib administered prior to chemotherapy in patients with metastatic triple-negative breast cancer

por Tan, Antoinette R., O’Shaughnessy, Joyce, Cao, Subing, Ahn, Sarah, Yi, John S.
Publicado 2023

Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study

por O’Shaughnessy, Joyce, Brezden-Masley, Christine, Cazzaniga, Marina, Dalvi, Tapashi, Walker, Graham, Bennett, James, Ohsumi, Shozo
Publicado 2020

A multidisciplinary approach to optimizing care of patients treated with alpelisib

por Rugo, Hope S., Lacouture, Mario E., Goncalves, Marcus D., Masharani, Umesh, Aapro, Matti S., O'Shaughnessy, Joyce A.
Publicado 2021

Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review

por Huang, Min, Haiderali, Amin, Fox, Grace E., Frederickson, Andrew, Cortes, Javier, Fasching, Peter A., O’Shaughnessy, Joyce
Publicado 2022

Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studie...

por O’Shaughnessy, Joyce, McIntyre, Kristi, Schwartzberg, Lee, Wilks, Sharon, Puhalla, Shannon, Berrak, Erhan, Song, James, Vahdat, Linda
Publicado 2015

Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurr...

por Puhalla, Shannon, Wilks, Sharon, Brufsky, Adam M, O’Shaughnessy, Joyce, Schwartzberg, Lee S, Berrak, Erhan, Song, James, Vahdat, Linda
Publicado 2016

Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer

por Schwartzberg, Lee, McIntyre, Kristi, Wilks, Sharon, Puhalla, Shannon, O’Shaughnessy, Joyce, Berrak, Erhan, He, Yaohua, Vahdat, Linda
Publicado 2019

Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis

por O’Shaughnessy, Joyce, Cortes, Javier, Twelves, Chris, Goldstein, Lori J., Alexis, Karenza, Xie, Ran, Barrios, Carlos, Ueno, Takayuki
Publicado 2020

Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer

por McIntyre, Kristi, O’Shaughnessy, Joyce, Schwartzberg, Lee, Glück, Stefan, Berrak, Erhan, Song, James X., Cox, David, Vahdat, Linda T.
Publicado 2014

Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer

por McIntyre, Kristi, O’Shaughnessy, Joyce, Schwartzberg, Lee, Glück, Stefan, Berrak, Erhan, Song, James X., Cox, David, Vahdat, Linda T.
Publicado 2014

Impact of race and tumor subtype on second malignancy risk in women with breast cancer

por Diab, Nicholas, Clark, Gary, Langer, Lucy, Wang, Yunfei, Hamlington, Barbara, Brzeskiewicz, Laura, O’Shaughnessy, Joyce, Diab, Sami, Jabbour, Salma K.
Publicado 2016

A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer

por Modi, Shanu, Saura, Cristina, Henderson, Charles, Lin, Nancy U., Mahtani, Reshma, Goddard, Jill, Rodenas, Eduardo, Hudis, Clifford, O’Shaughnessy, Joyce, Baselga, Jose
Publicado 2013

Efficacy and Safety of Weekly Paclitaxel With or Without Oral Alisertib in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial

por O’Shaughnessy, Joyce, McIntyre, Kristi, Wilks, Sharon, Ma, Ling, Block, Margaret, Andorsky, David, Danso, Michael, Locke, Tracy, Scales, Amy, Wang, Yunfei
Publicado 2021

Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribocic...

por Verma, Sunil, O’Shaughnessy, Joyce, Burris, Howard A., Campone, Mario, Alba, Emilio, Chandiwana, David, Dalal, Anand A., Sutradhar, Santosh, Monaco, Mauricio, Janni, Wolfgang
Publicado 2018